<DOC>
	<DOCNO>NCT01885910</DOCNO>
	<brief_summary>This pilot study explore continuation treatment treatment Aczone 5 % gel follow combination treatment doxycycline Aczone 5 % gel maintain therapeutic response .</brief_summary>
	<brief_title>Aczone 5 % Gel Maintenance Treatment Acne Vulgaris Following Completion Oral Doxycycline Aczone 5 % Gel</brief_title>
	<detailed_description>This two-center , open-label pilot study . The study apprise 7 study visit : Baseline Weeks 4 , 8 , 12 , 16 , 20 24 . All subject receive Aczone 5 % gel BID doxycycline 100mg mouth daily Baseline . Those subject achieve treatment response ( i.e. , IGA 0 , 1 2 ) Week 12 continue treatment Aczone 5 % gel BID Week 12 . Subjects achieve treatment response discontinue study participation .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<criteria>Outpatient , male female subject race , age 12 older . Female subject childbearing potential must negative urine pregnancy test result Baseline practice reliable method contraception throughout study ; Facial acne vulgaris characterize following : IGA Score &gt; 3 1050 facial inflammatory lesion ( papule , pustule ) 10100 facial noninflammatory lesion ( open/closed comedo ) Able understand comply requirement study sign Informed Consent/HIPAA Authorization form Female subject pregnant ( positive urine pregnancy test ) , breast feeding , childbearing potential practicing reliable method birth control . Allergy/sensitivity component test treatment ( Section 5.2 ) , lincomycin , tetracycline , sulfites . Subjects comply proper washout period prohibit medications/procedures ( Supplement 1 ) &gt; History clinically significant anemia hemolysis . History enteritis ( regional enteritis , ulcerative colitis , pseudomembranous colitis , antibioticassociated colitis ) . Skin disease/disorder might interfere diagnosis evaluation acne vulgaris Evidence recent alcohol drug abuse Medical condition , opinion Investigator , contraindicate subject 's participation clinical study History poor cooperation , noncompliance medical treatment unreliability Participation investigational drug study within 30 day baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>